Skip to main content

Table 7 Multiple Tobit regression adjusting for age and co-morbidities (left ear)

From: Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity

Frequency (Hz) No. of non-responses Risk factors
Estimate of coefficient (SE); p-value
HIV seropositive NCD
LFPTT
125 1 11.59 (3.69); 0.01 2.72 (2.81); 0.33
250 0 9.59 (4.11); 0.02 2.93 (3.14); 0.35
500 0 9.66 (4.6); 0.04 3.42 (3.52); 0.33
MFPTT
1000 0 6.74 (5.05); 0.18 2.91 (3.86); 0.45
2000 0 7.65 (4.98); 0.12 2.99 (3.81); 0.43
HFPTT
4000 1 9.68 (5.36); 0.07 7.19 (4.09); 0.08
8000 0 6.5 (6.37); 0.31 2.03 (4.87); 0.68
9000 1 1.02 (5.93); 0.86 5.29 (4.51); 0.24
EHFPTT
10,000 3 0.07 (6.18); 0.99 6.73 (4.68); 0.15
11,200 5 0.90 (6.0); 0.88 2.11 (4.55); 0.64
12,500 12 (14.6%) 2.87 (5.84)0.62 − 0.68 (4.42); 0.88
14,000 23 (28%) 8.25 (6.21); 0.18 6.11 (4.72); 0.19
16,000 50 (61%) − 1.3 (6.76); 0.85 11.35 (5.54); 0.04
18,000 68 (83%) 5.68 (12.71); 0.65 15.23 (10.54); 0.15
20,000 73 (89%) 1.75 (5.92); 0.77 5.56 (5.16); 0.28
  1. LFPTT, Low-frequency pure tone thresholds; MFPTT, Mid-frequency pure tone thresholds; HFPTT, High-frequency pure tone thresholds; EHFPTT, Extended high-frequency pure tone thresholds; NCD, Hypertension and Diabetes